Multicenter, therapeutic use observational study to evaluate the effects of concurrent therapy of Sarpogrelate on symptom improvement in patients with peripheral arterial disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004454

Enrollment

115

Registered

2019-11-21

Start date

2019-12-09

Completion date

Unknown

Last updated

2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : This study applies to evaluate the symptoms of peripheral vascular disease in patients with chronic arterial occlusion. It was planned to evaluate the degree of improvement. A single group, wil

EXERHERT Group&#39

will play the “Alchemist&#39

s Treasure” game by interlocking the step board and monitor. Test Group 2, &#39

Home Training Group&#39

, will consist of large muscle-oriented muscle exercises. The Subject will be provided with an image to exercise and perform a given exercise time according to the image.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients between the ages of 19 and 80 2. First administered or administered for less than three months of Sarpogrelate Hydrochloride to improve ischemic symptoms such as ulcers, pain and coldness caused by chronic arterial obstruction (Berger's disease, obstructive atherosclerosis, diabetic peripheral angiopathy, etc.) 3. Written informed consent by patient or his/her legal representative and agreed to participate in the study approved by the Institutional Review Board or ethics Committee

Exclusion criteria

Exclusion criteria: 1. Overall life expectancy < 2 year. 2. Any medically documented history of bleeding within a week of participating in the study 3. Persons with diseases that may increase bleeding during the study (Hemophilia, Capillary Placebo, Gastrointestinal Ulcers, Urinary Tract Bleeding, Hemoglobin, Vitreous Hemorrhage, etc.) 4. A female patient who is or may be pregnant 5. Female patients who are or will be breastfeeding during the study period 6. Patients who are not suitable for exercise therapy on their own due to cerebrovascular lesions, spinal diseases, muscle diseases, etc. 7. Patients with severe renal or hepatic disease

Design outcomes

Primary

Measure	Time frame
PAQ changes	—

Secondary

Measure	Time frame
Changes in each domain of PAQ;Variation of Body Measurements	—

Countries

Korea, Republic of

Contacts

Public Contactkyeoungim Jo

Kosin University Gospel Hospital

Outcome results